Pharmacopeia
GLP-1 receptor agonists
Core pharmacology
- Class Group
Incretin-based glucose-lowering medicines; examples of GLP-1 receptor agonists include semaglutide, liraglutide and dulaglutide. Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 RA.
- Main Action
Glucose-dependent stimulation of pancreatic insulin secretion; suppression of glucagon; delayed gastric emptying and reduced appetite.
- Mechanism of action
Agonism at the GLP-1 receptor (a G-protein-coupled receptor) activates intracellular cAMP signalling in pancreatic beta cells, promoting glucose-dependent insulin secretion. Central and gastrointestinal receptor actions influence satiety and gastric emptying.
- Indications Uses
Type 2 diabetes; selected agents are also indicated for chronic weight management and, according to product-specific indications, cardiorenal risk reduction. Use the specific product information rather than extrapolating indications across the class.
- Physiological effects
Improves glycaemic control with low intrinsic hypoglycaemia risk when given without insulin or secretagogues. Reduces appetite and weight; slows gastric emptying, most notably when treatment is initiated or escalated.
- Adverse Effects Toxicity
Common nausea, vomiting, diarrhoea and constipation; dehydration may follow gastrointestinal losses. Gallbladder events and pancreatitis are important cautions. Hypoglycaemia is more likely with concurrent insulin or sulfonylureas. Retained gastric contents may increase aspiration risk during anaesthesia or sedation.
- Special Points
Distinguish ACUTE ILLNESS from ELECTIVE PROCEDURES. ADA 2026 recommends holding GLP-1 RAs in acutely ill hospitalised patients; glycaemic control in the ICU is generally insulin based. ADS/ANZCA/GESA/NACOS elective periprocedural guidance (2025) recommends continuing GLP-1 RAs and dual GLP-1/GIP agents with a 24-hour clear-fluid diet, standard fasting and individualised aspiration precautions. Do not apply a universal one-week cessation rule.
Source references
These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.